

Synthesis of Pyrazoles by Treatment of 3-Benzylchromones, 3-Benzylflavones and Their 4-Thio Analogues with Hydrazine

Albert Lévai,^{*[a]} Artur M. S. Silva,^{*[b]} José A. S. Cavaleiro,^[b] Ibon Alkorta,^[c]
José Elguero,^[c] and József Jekő^[d]

Dedicated to Professor Dr. Miha Tisler on the occasion of his 80th birthday

Keywords: 3-Benzylchromones / 3-Benzylflavones / Hydrazine / Pyrazoles

The synthesis of pyrazoles **13–24** has been accomplished by treatment of 3-benzylchromones **1–5**, 3-benzylflavones **6–12** and their 4-thio analogues **25–29** with hydrazine hydrate in hot pyridine. A plausible reaction mechanism for the formation of pyrazoles **13–24** is discussed. A ¹H NMR study in [D₆]DMSO allowed the presence of both pyrazole annular tautomers to be observed, due to the presence of intramolec-

ular hydrogen bonds in each tautomer (OH--N and NH--O). GIAO/B3LYP/6-311++G** calculations were carried out on some model pyrazoles to provide a theoretical basis for the NMR experimental observations.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)

Introduction

Pyrazoles are well known five-membered nitrogen-containing heterocyclic compounds, and various procedures for their synthesis have been developed.^[1,2] Thanks to their diverse bioactivities, these compounds are useful substances in the development of agricultural products^[3] and in drug research.^[4] Another example of their application is the utilisation of *N*-(2-hydroxyphenyl)pyrazoles as photoprotectors of polystyrene,^[5,6] and *o*-hydroxyphenylpyrazoles have recently been used as ultraviolet stabilisers,^[6] analytical reagents,^[7] analgesic agents and platelet aggregation inhibitors.^[8] As a consequence of this wide range of applicability, numerous pyrazoles have already been synthesised.

We had previously started a systematic study on the synthesis of *o*-hydroxyphenylpyrazoles by treatment of various chromone derivatives with hydrazines. For this purpose, 2-styrylchromones,^[9] 2-methyl- and 2-phenylchromones^[10] and 3-aryl-5-hydroxyflavones^[11] had already been used as

starting materials, and simple and convenient procedures for the synthesis of new 3,4,5-trisubstituted pyrazoles in this way had been worked out as a result. The experience gained in the course of these studies prompted us to investigate the preparation of similar pyrazoles by treatment of 3-benzylchromones, 3-benzylflavones and their 4-thio analogues with hydrazines. In this paper, the reactions of these 3-substituted and 2,3-disubstituted chromone derivatives with hydrazine hydrate are reported.

Results and Discussion

Chemistry

In the course of our investigation into the reactions between chroman-4-ones or 1-thiochroman-4-ones and aromatic aldehydes in the presence of piperidine as a catalyst, it had been found that 3-benzylchromones or 3-benzylflavones are formed if the aldehydes bear strongly electron-withdrawing substituent(s).^[12] On the basis of this observation, we have developed a simple and convenient procedure for the synthesis of 3-benzylchromones, 3-benzylflavones and their 1-thio analogues.^[12] The preparation of the 4-thio analogues of all these substances has been accomplished by treatment with Lawesson's reagent,^[12–14] and these chromone derivatives have been utilised here as starting materials in their reaction with hydrazine hydrate.

We had previously carried out reactions between the related 3-(3-aryl-3-oxopropenyl)chromones and hydrazine in hot acetic acid; the chromone ring was opened under these

[a] Department of Organic Chemistry, University of Debrecen, P. O. Box 20, 4010 Debrecen, Hungary
Fax: +36-52-453836
E-mail: alevai@puma.unideb.hu

[b] Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
Fax: +351-234-370084
E-mail: arturs@dq.ua.pt

[c] Instituto de Química Médica, Juan de la Cierva, 3 28006 Madrid, Spain
Fax: +34-91-5644853
E-mail: iqmbel17@iqm.csic.es

[d] Department of Chemistry, College of Nyíregyháza, Sóstói u. 31/b, 4400 Nyíregyháza, Hungary

conditions to form the corresponding pyrazoles.^[15] However, when 3-benzylchromones **1–5** or 3-benzylflavones **6–12** were allowed to react with hydrazine hydrate in hot acetic acid, the unchanged starting material was recovered in each case, whilst if methanol was used as solvent, the reactions between compounds **1–12** and hydrazine hydrate proved to be too slow. On the basis of our preliminary experiments, pyridine was found to be a convenient solvent for this purpose.

Compounds **1–12** and hydrazine hydrate were allowed to react in hot pyridine, and pyrazoles **13–24** were obtained in good yields (67–82%) (Scheme 1).


The same pyrazoles **13, 14, 19, 22** and **23** were formed if 3-benzyl-4-thiochromones **25** and **26** and 3-benzyl-4-thioflavones **27–29** were treated with hydrazine hydrate under the same reaction conditions (Scheme 2).

It should also be mentioned that treatment of 3-(4-bromobenzyl)-1-thioflavone and 3-(3,4-dichlorobenzyl)-1-thioflavone with hydrazine hydrate in hot pyridine has been investigated, but no conversion occurred under these condi-


tions, indicating that the C–S bond cannot be cleaved by the nucleophilic attack of the hydrazine.

The structures of the new compounds **13–24** were elucidated by elemental analyses and by combined utilisation of various spectroscopic methods. The elemental analyses and mass spectra unequivocally established the presence of two nitrogen atoms in each reaction product. In the IR spectra (see Experimental Section), NH and C=N bands characteristic of a pyrazole ring were assigned in each case. A lack of a distinct hydroxy band may be a consequence of a bridged hydroxy group, with reference to the dominance of the **OH–N** tautomers in the tautomeric mixtures of **OH–N** and **NH–O** forms. Structure elucidation of all new pyrazoles was completed by NMR spectroscopy (vide infra).

A proposed reaction mechanism is illustrated in Scheme 3. The first step corresponds to a nucleophilic attack at the C-2 carbon atom of the chromone nucleus, followed by a ring-opening. A hydrazine derivative is formed as an intermediate and can react with the carbonyl (X = O) or thiocarbonyl group (X = S) in the molecule to form the




Scheme 1.



Scheme 2.

pyrazole ring. The obtained pyrazoles may exist as mixtures of **OH--N** and **NH--O** tautomers (Scheme 3).




Scheme 3.

NMR and Theoretical Study of the Tautomerism of Pyrazoles 13–24

The ^1H NMR spectra of compounds **13–24** in CDCl_3 each showed the presence of two broad singlets at $\delta = 10.1$ – 10.3 and 10.7 – 10.9 ppm, due to the resonances of the **NH** and **2'-OH** protons. Since the solubilities of some of these compounds in CDCl_3 are very small, we also measured the ^1H NMR spectra of compounds **13–24** in $[\text{D}_6]\text{DMSO}$. In each of these cases, however, four broad singlets at higher frequency values were observed (Table 1), indicating that pyrazoles **13–24** exist in $[\text{D}_6]\text{DMSO}$ as mixtures of tautomers (**OH--N** and **NH--O**; Scheme 4) while in CDCl_3 the proton exchange is too fast and only average signals were observed. The presence of the two tautomers in $[\text{D}_6]\text{DMSO}$ solution is not related to dilution, since we performed the

spectra at different concentrations and the four broad singlets were always observed. The assignment of the signals (since the ratios are not 50:50, those belonging to the same pyrazole are easily identifiable) is based on the calculated absolute shieldings (vide infra). In the cases of compounds **13–17** the **OH--N** tautomers are the more abundant (63%, $K \approx 1.7$), whilst in the cases of **18–24** the opposite applies, the **NH--O** tautomers being the major forms (59%, $K \approx 0.70$). This is the expected effect of the C-phenyl group,^[16] but if it is assumed that this effect should be independent of R^2 , the ratio of the K constants ($K_{\text{H}}/K_{\text{Ph}}$) should be constant. This is almost the case: on average they are 2.44 (between 2.35 and 2.57).



Scheme 4.

To fully characterise the structures of pyrazoles **13–24**, we added some drops of trifluoroacetic acid (TFA) to the $[\text{D}_6]\text{DMSO}$ solution to increase the prototropy. The main features of the NMR spectroscopic data for the pyrazoles **13–17** are the resonances of the methylene groups ($\delta_{\text{H}} = 3.85$ – 4.00 ppm, $\delta_{\text{C}} = 27.9$ – 30.0 ppm) and those of atoms H-


Table 1. Proton chemical shifts (δ , ppm) of OH and NH of pyrazoles **13–24** in $[\text{D}_6]\text{DMSO}$.

Compound	OH...N	NH	NH...O	OH	Ratio (%)	K
13 , $\text{R}^2 = 4\text{-Cl}$	13.11	10.96	12.68	9.88	66/34	1.941
14 , $\text{R}^2 = 4\text{-Br}$	13.11	10.96	12.70	9.31	63/37	1.703
15 , $\text{R}^2 = 4\text{-NO}_2$	13.13	10.80	12.75	9.89	61/39	1.564
16 , $\text{R}^2 = 2,4\text{-Cl}_2$	13.12	10.81	12.76	9.88	63/37	1.703
17 , $\text{R}^2 = 3,4\text{-Cl}_2$	13.10	10.78	12.72	9.89	62/38	1.632
18 , $\text{R}^2 = 2\text{-Cl}$	13.58	10.62	13.01	9.91	43/57	0.754
19 , $\text{R}^2 = 3\text{-Cl}$	13.48	10.53	12.94	9.90	41/59	0.695
20 , $\text{R}^2 = 4\text{-Cl}$	13.51	10.66	12.94	8.89	43/57	0.754
21 , $\text{R}^2 = 4\text{-Br}$	13.50	10.66	12.94	9.88	40/60	0.667
22 , $\text{R}^2 = 4\text{-NO}_2$	13.46	10.40	13.00	9.83	41/59	0.695
23 , $\text{R}^2 = 2,4\text{-Cl}_2$	13.55	10.45	13.04	9.93	41/59	0.695
24 , $\text{R}^2 = 3,4\text{-Cl}_2$	13.49	10.46	12.99	9.91	41/59	0.695

5 ($\delta_{\text{H}} = 7.90\text{--}8.08$ ppm), C-5 ($\delta_{\text{C}} = 133.6\text{--}134.4$ ppm) and C-2' ($\delta_{\text{C}} = 155.5\text{--}156.6$ ppm). The resonances of the quaternary carbons, especially for C-3 ($\delta_{\text{C}} = 142.9\text{--}143.5$ ppm) and C-4 ($\delta_{\text{C}} = 118.6\text{--}120.2$ ppm), have been assigned on the basis of the connectivities found in HMBC spectra (Figure 1). In the cases of compounds **13–24** in relation to **13–17** there are some signals due to the presence of the 5-aryl groups. The assignments of the resonances of the pyrazole ring carbons ($\delta_{\text{C-3}} = 144.7\text{--}145.4$ ppm, $\delta_{\text{C-4}} = 115.2\text{--}115.7$ ppm and $\delta_{\text{C-5}} = 145.7\text{--}146.5$ ppm) were also based on the connectivities found in the corresponding HMBC spectra (Figure 1).

We selected two pyrazoles, **14** and **15** (Scheme 5), in order to explore their structures in more detail, and in Table 2 we report the ^{13}C NMR signals of these two pyrazoles both

in solution ($[\text{D}_6]\text{DMSO} + \text{drops of TFA}$ to avoid broad unresolved signals) and in the solid state. It is known that, with very few exceptions (which should be apparent in their spectra), NH-pyrazoles exist in the solid state as only one tautomer.^[16–18]



Scheme 5.

The splitting observed for some signals in the CPMAS spectra does not correspond to a mixture of tautomers but to some solid-state effects. We have compared the experimentally measured data with the calculated σ values for both tautomers, and the results are reported in Table 3. The point corresponding to C-4'' of **14** (C–Br) was not used in the regressions because the carbon atoms bearing heavy atoms are not well calculated.^[19,20] We treated **14** and **15** together because the individual equations were very similar.




Figure 1. Main connectivities found in the HMBC spectra of pyrazoles **13–24**.

Table 2. ^{13}C chemical shifts (δ , ppm) and absolute shieldings (σ , ppm) of pyrazoles **14** and **15**.

Carbon atom	Solution	Solid-state 14	Shielding OH--N	Shielding NH--O
C-1'	114.9	116.0	61.3028	58.2479
C-2'	156.1	155.2	16.2644	23.7988
C-3'	116.8	117.0	59.3555	64.0356
C-4'	131.1	128.4	47.9487	51.5705
C-5'	119.7	117.0	60.7412	55.9917
C-6'	130.8	125.9	52.2124	51.0474
C-Ar	143.0	145.2 ^[a]	26.2113	43.9166
C-4	119.6	117.0	57.2644	59.0052
C-H	133.9	132.8	49.0684	36.7606
CH ₂	29.4	34.0	144.3961	143.7494
C-1''	139.8	139.7 ^[b]	37.0847	37.3344
C-2'',6''	131.1	132.0	46.8519	46.4592
C-3'',5''	131.8	132.0	45.1710	45.4290
C-4''	119.9	118.1	36.5350	37.0812
Carbon atom	Solution	Solid-state 15	Shielding OH--N	Shielding NH--O
C-1'	114.6	114.9	61.6602	58.6028
C-2'	156.4	155.9	16.2210	24.2397
C-3'	117.8	118.0	59.0704	63.7022
C-4'	132.4	128.8	47.5930	50.8207
C-5'	120.1	120.8	60.5880	55.8768
C-6'	131.3	130.3	52.4544	50.8641
C-Ar	148.5	147.0	26.1381	36.2125
C-4	119.4	119.4	58.5777	60.5592
C-H	134.4	131.2	49.3626	43.2217
CH ₂	30.5	30.5	143.5382	142.8670
C-1''	143.5	145.6	27.7899	27.3892
C-2'',6''	130.3	128.8	48.0791	47.7413
C-3'',5''	124.2	122.3 ^[c]	52.6231	52.8009
C-4''	147.1	146.7	28.8127	28.9622

[a] Average of two split signals at 144.5 and 146.0 ppm. [b] Average of two split signals at 138.8 and 140.6 ppm. [c] Average of two split signals at 121.4 and 123.2 ppm.

Table 3. Results of linear regressions (experimental δ vs. calculated σ , TMS, $\sigma = 177$ ppm).^[21]

Compound	No. of points ^[a]	Tautomer	Intercept	Slope	r^2
14+15 solid	32	OH--N	(175.7 \pm 0.9)	-(0.983 \pm 0.014)	0.994
	32	NH--O	(178.1 \pm 1.0)	-(1.011 \pm 0.019)	0.989
14+15 solution	32	OH--N	(177.1 \pm 1.2)	-(0.998 \pm 0.018)	0.990
	32	NH--O	(179.6 \pm 1.2)	-(1.029 \pm 0.018)	0.991
	32	50:50	(178.7 \pm 0.8)	-(1.019 \pm 0.012)	0.996

[a] The point corresponding to 4'' of **14** (C-Br) has been omitted.

The correlation coefficients of Table 3 indicate that the tautomer present in the solid state is the **OH--N** form, while in solution the best result is obtained with a 50:50 mixture of both tautomers. Although the experimentally determined ratios are 63:37 (**14**) and 61:39 (**15**) it is not possible to refine the 50:50 model further.

Having established the validity of our σ calculations for the ¹³C NMR results, we will now turn to the ¹H NMR results. If we limit ourselves to the OH and NH signals of compounds **14** and **15** (Table 4), a plot of these data (Figure 2) shows that the assignment of these signals (used to determine the ratios of Table 1) is correct.

Table 4. ¹H NMR chemical shifts (δ , ppm) and absolute shieldings (σ , ppm) of the OH and NH signals of compounds **14** and **15**.

Pyrazole	Tautomer	Group	δ	σ
14	OH--N	OH	13.13	20.6479
		NH	10.80	23.1732
	NH--O	OH	9.89	27.5744
		NH	12.75	20.4029
15	OH--N	OH	13.11	20.7087
		NH	10.96	23.1616
	NH--O	OH	9.31	27.5346
		NH	12.70	20.3333




Figure 2. The line corresponds to the equation $\delta = (36.2 \pm 1.4) - (1.12 \pm 0.06) \sigma$, $n = 7$, $r^2 = 0.91$, $\sigma(\text{TMS}) = 31.97$.^[21]

The calculated regression line was calculated by removing the OH signals not involved in hydrogen bonds (**NH--O** tautomers). Even so, the correlation is not very good

because some signals are very sensitive to medium effects, but it suffices for our purpose.

Since we had carried out B3LYP/6-311++G** calculations prior to the GIAO ones, here we report the corresponding energies (Table 5).

Table 5. Energies (absolute values in Hartrees, relative values in kJ·mol⁻¹).

Compound	NH--O	OH--N	E_{rel}	E_{rel} (DMSO)
14	-3376.6013	-3376.6100	22.7	12.1
15	-1007.6230	-1007.6308	20.7	11.5

Even with correction for the solvent effect (continuum model, see computational details) the stability of the **OH--N** tautomer is overestimated (at 300 K, the average experimental values correspond to 1.1–1.2 kJ·mol⁻¹). Probably the DMSO produces some specific effects, such as intermolecular hydrogen bonds. The most important conclusion from Table 5, however, is that there is no difference between the 4-Br and the 4-NO₂ derivatives in what tautomerism is involved, not a surprising result if the presence of a CH₂ group between the phenyl and the pyrazole rings is taken into account.

Experimental Section

General Remarks: Melting points were measured with a Kofler hot-stage apparatus and are uncorrected. IR (KBr) spectra were recorded with Perkin–Elmer 16 PC and MATTSON 7000 FTIR spectrometers. Mass spectra were recorded with a VG Trio-2 instrument. Elemental analyses were obtained with a Carlo–Erba 1106 apparatus. ¹H and ¹³C NMR spectra were recorded with a Bruker Avance 300 spectrometer (at 300.13 and 75.47 MHz, respectively) in [D₆]DMSO plus some drops of TFA; chemical shifts are reported in ppm (δ) with TMS as internal reference, and coupling constants (J) are given in Hz. The ¹H unequivocal assignments were made by 2D gCOSY experiments, while ¹³C assignments were made with the aid of 2D gHSQC and gHMBC (delays for one-bond and long-range J C/H couplings were optimised for 145 and 7 Hz, respectively) experiments. Starting materials **1–12** and **25–29** were synthesised by known procedures.^[12,13]

Treatment of 3-Benzylchromones 1–5, 3-Benzylflavones 7–12 and Their 4-Thio Analogues 25–29 with Hydrazine Hydrate: A mixture of the appropriate starting material (**1–12** and **25–29**, 5.0 mmol), hydrazine hydrate (50.0 mmol) and pyridine (30 mL) was heated at reflux for 8 h, and then poured into water. The precipitate was filtered off, washed with water, dried and recrystallised from methanol to afford pyrazoles **13–24** (Scheme 1 and Scheme 2).

4-(4-Chlorobenzyl)-3(5)-(2-hydroxyphenyl)pyrazole (13): Yields 1.20 g (84.5%) (from **1**) and 1.17 g (82.4%) (from **25**). M.p. 140–141 °C (recrystallised from methanol). ¹H NMR: δ = 3.90 (s, 2 H, CH₂), 6.86 (dt, J = 7.5 and 1.0 Hz, 1 H, 5'-H), 7.00 (dd, J = 8.1 and 1.0 Hz, 1 H, 3'-H), 7.14 (d, J = 8.4 Hz, 2 H, 2'',6''-H), 7.27 (d, J = 8.4 Hz, 2 H, 3'',5''-H), 7.24–7.31 (m, 2 H, 4'-H and 6'-H), 7.90 (s, 1 H, 5-H) ppm. ¹³C NMR: δ = 29.2 (CH₂), 115.5 (C-1'), 116.5 (C-3'), 118.6 (C-4), 119.3 (C-5'), 128.5 (C-3'',5''), 130.2 (C-6'), 130.4 (C-2'',6''), 130.9 (C-4'), 131.1 (4'), 133.6 (C-5), 139.4 (C-1''), 142.9 (C-3), 155.7 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3259, 1594, 1492, 1457, 1405, 1292, 1263, 1245, 1089, 848, 827, 740, 713 cm⁻¹. MS: m/z = 284 [M]⁺ (89), 256 (28), 173 (59), 125 (100). C₁₆H₁₃ClN₂O (284.71): calcd. C 67.49, H 4.60, N 9.83; found C 67.58, H 4.66, N 9.91.

4-(4-Bromobenzyl)-3(5)-(2-hydroxyphenyl)pyrazole (14): Yields 1.28 g (77.8%) (from **2**) and 1.25 g (76.0%) (from **26**). M.p. 153–154 °C. ¹H NMR: δ = 3.86 (s, 2 H, CH₂), 6.86 (dt, J = 7.5 and 1.0 Hz, 1 H, 5'-H), 7.01 (dd, J = 8.8 and 1.0 Hz, 1 H, 3'-H), 7.05 (d, J = 8.4 Hz, 2 H, 2'',6''-H), 7.25–7.30 (m, 2 H, 4'-H and 6'-H), 7.37 (d, J = 8.4 Hz, 2 H, 3'',5''-H), 7.99 (s, 1 H, 5-H) ppm. ¹³C NMR: δ = 29.4 (CH₂), 114.9 (C-1'), 116.8 (C-3'), 119.6 (C-4), 119.7 (C-5'), 119.9 (C-4''), 130.8 (C-6'), 131.1 (C-4' and C-2'',6''), 131.8 (C-3'',5''), 133.9 (C-5), 139.8 (C-1''), 143.0 (C-3), 156.1 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3261, 1592, 1486, 1457, 1290, 1261, 1070, 1010, 846, 827, 740, 715 cm⁻¹. MS: m/z = 328/330 [M]⁺ (84/84), 300/302 (16/16), 249 (13), 171 (100). C₁₆H₁₃BrN₂O (329.17): calcd. C 58.38, H 3.98, N 8.51; found C 58.47, H 3.92, N 8.60.

3(5)-(2-Hydroxyphenyl)-4-(4-nitrobenzyl)pyrazole (15): Yield 1.01 g (68.5%). M.p. 173–174 °C (recrystallised from methanol). ¹H NMR: δ = 4.00 (s, 2 H, CH₂), 6.83 (t, J = 7.4 Hz, 1 H, 5'-H), 6.98 (d, J = 8.1 Hz, 1 H, 3'-H), 7.21–7.29 (m, 2 H, 4'-H and 6'-H), 7.31 (d, J = 8.6 Hz, 2 H, 2'',6''-H), 8.02 (d, J = 8.6 Hz, 2 H, 3'',5''-H), 8.06 (s, 1 H, 5-H) ppm. ¹³C NMR: δ = 30.0 (CH₂), 114.6 (C-1'), 117.8 (C-3'), 119.4 (C-4), 120.1 (C-5'), 124.2 (C-3'',5''), 130.3 (C-2'',6''), 131.3 (C-6'), 132.4 (C-4'), 134.4 (C-5), 143.5 (C-3), 147.1 (C-4''), 148.5 (C-1''), 156.4 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3374, 1583, 1504, 1450, 1346, 1253, 1083, 854, 842, 754, 730, 717 cm⁻¹. MS: m/z = 295 [M]⁺ (100), 278 (45), 265 (30), 248 (38). C₁₆H₁₃N₃O₃ (295.26): calcd. C 65.08, H 4.43, N 14.22; found C 65.17, H 4.49, N 14.31.

4-(2,4-Dichlorobenzyl)-3(5)-(2-hydroxyphenyl)pyrazole (16): Yield 1.13 g (71.1%). M.p. 143–144 °C (recrystallised from methanol). ¹H NMR: δ = 3.92 (s, 2 H, CH₂), 6.85 (d, J = 7.5 Hz, 1 H, 5'-H), 7.00 (d, J = 8.1 Hz, 1 H, 3'-H), 7.08 (d, J = 8.3 Hz, 1 H, 6''-H), 7.16 (dd, J = 8.3 and 2.1 Hz, 1 H, 5''-H), 7.22–7.30 (m, 2 H, 4'-H and 6'-H), 7.39 (d, J = 2.1 Hz, 1 H, 3''-H), 7.95 (s, 1 H, 5-H) ppm. ¹³C NMR: δ = 27.9 (CH₂), 114.7 (C-1'), 117.2 (C-3'), 118.9 (C-4), 120.1 (C-5'), 128.1 (C-5''), 129.7 (C-3''), 131.3 (C-6'), 132.6 (C-4' and C-6''), 133.2 (C-4''), 134.3 (C-5), 134.9 (C-2''), 136.9 (C-1''), 143.5 (C-3), 156.6 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3347, 1587, 1473, 1457, 1442, 1286, 1257, 1089, 1049, 877, 854, 829, 728 cm⁻¹. MS: m/z = 318 [M]⁺ (83), 283 (35), 173 (51), 159 (100). C₁₆H₁₂Cl₂N₂O (319.17): calcd. C 60.21, H 3.79, N 8.77; found C 60.14, H 3.83, N 8.67.

4-(3,4-Dichlorobenzyl)-3(5)-(2-hydroxyphenyl)pyrazole (17): Yield 1.24 g (78.0%). M.p. 133–134 °C (recrystallised from methanol). ¹H NMR: δ = 3.85 (s, 2 H, CH₂), 6.85 (dt, J = 7.5 and 1.0 Hz, 1 H, 5'-H), 6.99 (d, J = 7.5 Hz, 1 H, 3'-H), 7.01 (dd, J = 8.2 and 2.2 Hz, 1 H, 6''-H), 7.27 (d, J = 2.2 Hz, 1 H, 2''-H), 7.22–7.30 (m, 2 H, 4'-H and 6'-H), 7.35 (d, J = 8.2 Hz, 1 H, 5''-H), 8.08 (s, 1 H, 5-H) ppm. ¹³C NMR: δ = 29.3 (CH₂), 114.5 (C-1'), 117.5 (C-3'), 120.1 and 120.2 (C-4 and C-5'), 129.5 (C-6''), 130.1 (C-4''), 131.1

and 131.3 (C-2'' and C-5''), 131.5 (C-6'), 132.2 (C-3''), 132.7 (C-4'), 134.4 (C-5), 141.5 (C-1''), 143.3 (C-3), 155.5 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3265, 1592, 1514, 1471, 1454, 1259, 1238, 1129, 1088, 1011, 832, 745 cm⁻¹. MS: m/z = 318 [M]⁺ (100), 290 (22), 173 (77), 159 (87). C₁₆H₁₂Cl₂N₂O (319.17): calcd. C 60.21, H 3.79, N 8.77; found C 60.31, H 3.73, N 8.85.

4-(2-Chlorobenzyl)-3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole (18): Yield 1.39 g (77.2%). M.p. 189–190 °C (recrystallised from methanol). ¹H NMR: δ = 4.04 (s, 2 H, CH₂), 6.77 (dt, J = 7.5 and 0.8 Hz, 1 H, 5'-H), 6.90 (dt, J = 7.5 and 1.9 Hz, 1 H, 6''-H), 6.97 (dd, J = 7.6 and 0.8 Hz, 1 H, 3'-H), 6.96–7.07 (m, 2 H, 4'-H and 5''-H), 7.18 (dd, J = 7.5 and 1.5 Hz, 1 H, 6'-H), 7.19–7.25 (m, 1 H, 4'-H), 7.24 (dd, J = 7.7 and 1.6 Hz, 1 H, 3''-H), 7.38–7.42 (m, 3 H, 3''',4''',5'''-H), 7.47–7.50 (m, 2 H, 2''',6'''-H) ppm. ¹³C NMR: δ = 27.7 (CH₂), 115.2 and 115.3 (C-1' and C-4), 117.2 (C-3'), 120.0 (C-5'), 127.7 (C-5''), 127.78, 128.86 and 129.0 (C-4'', C-1''' and C-2''',6'''), 129.8 (C-3''',5'''), 130.0 (C-3''), 130.4 (C-4''), 130.6 (C-6''), 131.1 (C-6'), 132.3 (C-4'), 133.9 (C-2''), 137.3 (C-1''), 145.3 (C-3), 146.3 (C-5), 156.6 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3365, 1589, 1504, 1467, 1454, 1388, 1249, 1176, 1037, 981, 827, 767, 754, 692 cm⁻¹. MS: m/z = 360 [M]⁺, (7), 345 (10), 311 (100), 233 (11). C₂₂H₁₇ClN₂O (360.80): calcd. C 73.23, H 4.75, N 7.76; found C 73.29, H 4.61, N 7.85.

4-(3-Chlorobenzyl)-3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole (19): Yields 1.39 g (77.2%) (from **7**) and 1.32 g (73.3%) (from **27**). M.p. 175–176 °C (recrystallised from methanol). ¹H NMR: δ = 4.01 (s, 2 H, CH₂), 6.83 (ddd, J = 7.7, 7.3 and 1.0 Hz, 1 H, 5'-H), 6.89 (dt, J = 7.7 and 1.0 Hz, 1 H, 4''-H), 6.96 (t, J = 1.8 Hz, 1 H, 2''-H), 6.99 (d, J = 7.8 Hz, 1 H, 3'-H), 7.05 (dt, J = 7.7 and 1.8 Hz, 1 H, 6''-H), 7.10 (t, J = 7.7 Hz, 1 H, 5''-H), 7.26 (d, J = 7.3 Hz, 1 H, 6'-H), 7.23–7.30 (m, 1 H, 4'-H), 7.42–7.45 (m, 3 H, 3''',4''',5'''-H), 7.51–7.56 (m, 2 H, 2''',6'''-H) ppm. ¹³C NMR: δ = 28.9 (CH₂), 115.4 (C-1'), 115.7 (C-4), 116.9 (C-3'), 119.8 (C-5'), 126.7 (C-6''), 127.1 (C-4''), 128.4 (C-2''), 128.8 (C-2''',6'''), 128.9 (C-1'''), 129.6 (C-3''',5'''), 130.3 (C-4'''), 130.5 (C-5''), 131.1 (C-6'), 132.0 (C-4'), 133.8 (C-3''), 142.7 (C-1''), 144.8 (C-3), 145.9 (C-5), 156.3 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3365, 1585, 1504, 1451, 1382, 1247, 1166, 1133, 979, 925, 865, 829, 767, 690 cm⁻¹. MS: m/z = 360 [M]⁺, (27), 345 (100), 311 (7), 233 (38). C₂₂H₁₇ClN₂O (360.80): calcd. C 73.23, H 4.75, N 7.76; found C 73.16, H 4.69, N 7.70.

4-(4-Chlorobenzyl)-3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole (20): Yield 1.37 g (76.1%). M.p. 208–209 °C (recrystallised from methanol). ¹H NMR: δ = 4.00 (s, 2 H, CH₂), 7.82 (dt, J = 7.5 and 0.9 Hz, 1 H, 5'-H), 6.95–7.00 (m, 3 H, 3'-H and 2'',6''-H), 7.14 (d, J = 8.4 Hz, 2 H, 3'',5''-H), 7.23 (d, J = 7.6 Hz, 1 H, 6'-H), 7.22–7.28 (m, 1 H, 4'-H), 7.41–7.45 (m, 3 H, 3''',4''',5'''-H) 7.52–7.56 (m, 2 H, 2''',6'''-H) ppm. ¹³C NMR: δ = 29.6 (CH₂), 115.5 and 115.6 (C-1' and C-4), 116.8 (C-3'), 119.7 (C-5'), 128.6 (C-2''',6'''), 128.7 (C-3'',5''), 129.2 (C-1'''), 129.5 (C-3''',5'''), 130.0 (C-4'''), 130.1 (C-2'',6''), 130.9 (C-6'), 131.3 (C-4''), 131.6 (C-4'), 139.2 (C-1''), 144.7 (C-3), 145.7 (C-5), 156.2 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3374, 1585, 1504, 1488, 1452, 1247, 1130, 1110, 933, 908, 748, 694 cm⁻¹. MS: m/z = 360 [M]⁺, (17), 345 (25), 124 (47), 109 (100). C₂₂H₁₇ClN₂O (360.80): calcd. C 73.23, H 4.75, N 7.76; found C 73.32, H 4.79, N 7.68.

4-(4-Bromobenzyl)-3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole (21): Yield 1.58 g (78.0%). M.p. 211–212 °C (recrystallised from methanol). ¹H NMR: δ = 3.99 (s, 2 H, CH₂), 6.83 (t, J = 7.8 Hz, 1 H, 5'-H), 6.91 (d, J = 8.4 Hz, 2 H, 2'',6''-H), 6.98 (d, J = 7.8 Hz, 1 H, 3'-H), 7.26 (d, J = 7.8 Hz, 1 H, 6'-H), 7.25–7.29 (m, 1 H, 4'-H), 7.28 (d, J = 8.4 Hz, 2 H, 3'',5''-H), 7.41–7.45 (m, 3 H, 3''',4''',5'''-H), 7.53–7.56 (m, 2 H, 2''',6'''-H) ppm. ¹³C NMR: δ

= 28.7 (CH₂), 115.5 and 115.6 (C-1' and C-4), 116.8 (C-3'), 119.72 and 119.76 (C-5' and C-4''), 128.6 (C-2''',6'''), 129.1 (C-1'''), 129.5 (C-3''',5'''), 130.1 (C-4'''), 130.6 (C-2'',6''), 130.9 (C-6'), 131.7 (C-4' and C-3'',5''), 139.6 (C-1''), 144.8 (C-3), 145.8 (C-5), 156.2 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3376, 1583, 1504, 1484, 1452, 1288, 1249, 1180, 1164, 1130, 1070, 1010, 981, 827, 792, 748, 694 cm⁻¹. MS: m/z = 404/406 [M]⁺ (100/100), 389/391 (17/17), 325 (14), 249 (43). C₂₂H₁₇BrN₂O (405.27): calcd. C 65.19, H 4.23, N 6.91; found C 65.26, H 4.27, N 6.83.

3(5)-(2-Hydroxyphenyl)-4-(4-nitrobenzyl)-5(3)-phenylpyrazole (22): Yields 1.24 g (66.8%) (from **10**) and 1.41 g (76.0%) (from **28**). M.p. 224–225 °C (recrystallised from methanol). ¹H NMR: δ = 4.13 (s, 2 H, CH₂), 6.79 (t, J = 7.5 Hz, 1 H, 5'-H), 6.95 (d, J = 8.5 Hz, 1 H, 3'-H), 7.18 (d, J = 8.5 Hz, 2 H, 2'',6''-H), 7.20 (d, J = 7.5 Hz, 1 H, 6'-H), 7.20–7.25 (m, 1 H, 4'-H), 7.37–7.41 (m, 3 H, 3''',4''',5'''-H), 7.50–7.54 (m, 2 H, 2''',6'''-H), 7.92 (d, J = 8.5 Hz, 2 H, 3'',5''-H) ppm. ¹³C NMR: δ = 29.6 (CH₂), 115.4 and 115.5 (C-1' and C-4), 117.1 (C-3'), 120.0 (C-5'), 124.1 (C-3'',5''), 129.0 (C-1''' and C-2''',6'''), 129.8 and 129.9 (C-2'',6'' and C-3''',5'''), 130.5 (C-4'''), 131.3 (C-6'), 132.2 (C-4'), 145.1 (C-3), 146.2 (C-5), 146.9 (C-1''), 148.5 (C-4''), 156.5 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3361, 1594, 1511, 1452, 1346, 1249, 1164, 1133, 1109, 977, 846, 771, 750, 732, 700, 593 cm⁻¹. MS: m/z = 371 (100) [M]⁺, 341 (30), 247 (27), 146 (48). C₂₂H₁₇N₃O₃ (371.36): calcd. C 71.15, H 4.62, N 7.54; found C 71.23, H 4.68, N 7.62.

4-(2,4-Dichlorobenzyl)-3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole (23): Yields 1.52 g (77.2%) (from **11**) and 1.69 g (85.8%) (from **29**). M.p. 206–207 °C (recrystallised from methanol). ¹H NMR: δ = 3.99 (s, 2 H, CH₂), 6.78 (ddd, J = 7.6, 7.5 and 1.0 Hz, 1 H, 5'-H), 6.88 (d, J = 8.3 Hz, 1 H, 6'-H), 6.94 (dd, J = 8.2 and 1.0 Hz, 1 H, 3'-H), 7.00 (dd, J = 8.3 and 2.1 Hz, 1 H, 5''-H), 7.16 (dd, J = 7.6 and 1.6 Hz, 1 H, 6'-H), 7.22 (ddd, J = 8.2, 7.5 and 1.6 Hz, 1 H, 4'-H), 7.29 (d, J = 2.1 Hz, 1 H, 3''-H), 7.39–7.42 (m, 3 H, 3''',4''',5'''-H), 7.47–7.50 (m, 2 H, 2''',6'''-H) ppm. ¹³C NMR: δ = 27.5 (CH₂), 115.2 and 115.3 (C-4 and C-1'), 117.2 (C-3'), 120.1 (C-5'), 127.8 (C-5''), 128.8 (C-1'''), 129.1 (C-2''',6'''), 129.5 (C-3''), 129.9 (C-3''',5'''), 130.8 (C-4'''), 131.3 (C-6'), 131.9 (C-6''), 132.5 (C-4'), 132.9 (C-4''), 134.8 (C-2''), 136.5 (C-1''), 145.4 (C-3), 146.5 (C-5), 156.7 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3359, 1587, 1504, 1467, 1454, 1413, 1292, 1249, 1172, 1103, 1047, 979, 908, 867, 831, 771, 750, 698, 595 cm⁻¹. MS: m/z = 394 [M]⁺ (100), 359 (85), 249 (27), 146 (77). C₂₂H₁₆Cl₂N₂O (395.26): calcd. C 66.85, H 4.08, N 7.08; found C 66.94, H 4.13, N 6.98.

4-(3,4-Dichlorobenzyl)-3(5)-(2-hydroxyphenyl)-5(3)-phenylpyrazole (24): Yield 1.32 g (67.0%). M.p. 192–193 °C (recrystallised from methanol). ¹H NMR: δ = 3.99 (s, 2 H, CH₂), 6.94 (dd, J = 7.5 and 7.4 Hz, 1 H, 5'-H), 6.89 (dd, J = 8.3 and 2.0 Hz, 1 H, 6'-H), 6.98 (d, J = 8.1 Hz, 1 H, 3'-H), 7.11 (d, J = 2.0 Hz, 1 H, 2''-H), 7.22 (d, J = 7.5 Hz, 1 H, 6'-H), 7.24 (dd, J = 8.1 and 7.4 Hz, 1 H, 4'-H), 7.25 (d, J = 8.3 Hz, 1 H, 5''-H), 7.37–7.45 (m, 3 H, 3''',4''',5'''-H), 7.52–7.56 (m, 2 H, 2''',6'''-H) ppm. ¹³C NMR: δ = 28.7 (CH₂), 115.53 and 115.55 (C-4 and C-1'), 117.0 (C-3'), 119.9 (C-5'), 128.8 (C-6''), 128.9 (C-2''',6'''), 129.1 (C-1'''), 129.6 (C-4''), 129.7 (C-3''',5'''), 130.3 (C-4'''), 130.7 (C-2''), 130.9 (C-5''), 131.2 (C-6'), 131.8 (C-4'), 132.0 (C-3''), 141.3 (C-1''), 144.9 (C-3), 146.1 (C-5), 156.5 (C-2') ppm. IR (KBr): $\tilde{\nu}$ = 3376, 1585, 1504, 1469, 1452, 1388, 1247, 1166, 1130, 1029, 979, 919, 827, 769, 750, 694, 580 cm⁻¹. MS: m/z = 394 [M]⁺ (100), 359 (10), 249 (39), 146 (62). C₂₂H₁₆Cl₂N₂O (395.26): calcd. C 66.85, H 4.08, N 7.08; found C 66.78, H 4.03, N 7.14.

Computational Details: Geometries of compounds **14** and **15** were fully optimised at the B3LYP theoretical level,^[22] with the 6-

311++G** basis set^[23] as implemented in the Gaussian 03 program.^[24] Harmonic frequency calculations verified the nature of the stationary points as minima (all real frequencies). Absolute shieldings of compounds **14** and **15** were calculated over the fully optimised geometries within the GIAO approximation.^[25] The Miertus, Scrocco and Tomasi continuum model was used for the calculation of solvent effects.^[26]

Acknowledgments

Thanks are due to the Hungarian Scientific Research Fund (Grant No. OTKA T049468) and also to the University of Aveiro, FCT and FEDER for funding the Organic Chemistry Research Unit. The technical assistance of Mrs. M. Nagy and Mr. L. Szabó is highly appreciated.

- [1] J. Elguero, in: *Comprehensive Heterocyclic Chemistry* (Eds.: A. R. Katritzky, C. W. Rees), Pergamon Press, Oxford, **1984**, Vol. 5, 167–303.
- [2] J. Elguero, in: *Comprehensive Heterocyclic Chemistry II* (Eds.: A. R. Katritzky, C. W. Rees, E. F. Scriven), Pergamon Press, Oxford, **1996**, vol. 3, 1–75.
- [3] T. Eicher, S. Hauptmann, *The Chemistry of Heterocycles – Structure, Reactions, Synthesis and Application* (Translated by H. Suschitzky and J. Suschitzky), Georg Thieme Verlag, Stuttgart, **1995**, 184.
- [4] J. Elguero, P. Goya, N. Jagerovic, A. M. S. Silva, *Pyrazoles as Drugs: Facts and Fantasies*, in: *Targets in Heterocyclic Systems – Chemistry and Properties* (Eds.: O. A. Attanasi and D. Spinelli), Italian Society of Chemistry, **2002**, vol. 6, 52–98.
- [5] J. Catalán, F. Fabero, M. S. Guijano, R. M. Claramunt, M. D. S. Maria, M. C. Foces-Foces, F. H. Cano, J. Elguero, R. Sastre, *J. Am. Chem. Soc.* **1990**, *112*, 747–759.
- [6] J. Catalán, F. Fabero, R. M. Claramunt, M. D. S. Maria, M. C. Foces-Foces, F. H. Cano, M. Martinez-Ripoll, J. Elguero, R. Sastre, *J. Am. Chem. Soc.* **1992**, *114*, 5039–5048.
- [7] R. Ahmad, N. Ahmad, M. Zia-Ul-Haq, A. Wahid, *J. Chem. Soc. Pak.* **1996**, *18*, 38–41.
- [8] K. Takagi, M. Tanaka, Y. Murakami, H. Morita, T. Aotsuka, *Eur. J. Med. Chem. – Chim. Ther.* **1986**, *21*, 65–69.
- [9] D. C. G. A. Pinto, A. M. S. Silva, J. A. S. Cavaleiro, C. Foces-Foces, A. L. Llamas-Saiz, N. Jagerovic, J. Elguero, *Tetrahedron* **1999**, *55*, 10187–10200.
- [10] D. C. G. A. Pinto, A. M. S. Silva, J. A. S. Cavaleiro, *J. Heterocycl. Chem.* **2000**, *37*, 1629–1634.
- [11] D. C. G. A. Pinto, A. M. S. Silva, L. M. P. M. Almeida, J. A. S. Cavaleiro, J. Elguero, *Eur. J. Org. Chem.* **2002**, 3807–3815.
- [12] a) A. Lévai, Z. Dinya, J. B. Schäg, G. Tóth, Á. Szöllösy, *Pharmazie* **1981**, *36*, 465–466; b) A. Lévai, Á. Szöllösy, G. Tóth, *Acta Chim. Hung.* **1991**, *128*, 359–364; c) A. Lévai, Z. Szabó, *Bull. Soc. Chim. Fr.* **1991**, *128*, 976–978; d) A. Lévai, Z. Szabó, *J. Chem. Research (S)* **1992**, 380–381.
- [13] A. Lévai, *J. Chem. Research (S)* **1992**, 163–163.
- [14] B. S. Pedersen, S. Scheibye, H. H. Nilsson, S. O. Lawesson, *Bull. Soc. Chim. Belges* **1978**, *87*, 223–227.
- [15] A. Lévai, A. M. S. Silva, D. C. G. A. Pinto, J. A. S. Cavaleiro, I. Alkorta, J. Elguero, J. Jekő, *Eur. J. Org. Chem.* **2004**, 4672–4679.
- [16] V. I. Minkin, A. D. Garnovskii, J. Elguero, A. R. Katritzky, O. V. Denisko, *Adv. Heterocycl. Chem.* **2000**, *76*, 157–323.
- [17] R. M. Claramunt, M. Á. García, C. López, S. Trofimenko, G. P. A. Yap, I. Alkorta, J. Elguero, *Magn. Reson. Chem.* **2005**, *43*, 89–91.
- [18] R. M. Claramunt, C. López, J. Elguero, *ARKIVOC* **2006**, v, 5–11.
- [19] O. Prakash, A. Kumar, A. Sadana, R. Prakash, S. P. Singh, R. M. Claramunt, D. Sanz, I. Alkorta, J. Elguero, *Tetrahedron* **2005**, *61*, 6642–6651.

- [20] R. M. Claramunt, C. López, M. A. García, M. D. Otero, M. R. Torres, E. Pinilla, S. H. Alarcón, I. Alkorta, J. Elguero, *New J. Chem.* **2001**, 25, 1061–1068.
- [21] I. Alkorta, J. Elguero, *Int. J. Mol. Sci.* **2003**, 4, 64–92.
- [22] a) A. D. Becke, *J. Chem. Phys.* **1993**, 98, 5648–5652; b) C. Lee, W. Yang, R. G. Parr, *Phys. Rev. B* **1988**, 37, 785–789.
- [23] R. Ditchfield, W. J. Hehre, J. A. Pople, *J. Chem. Phys.* **1971**, 54, 724–728; M. J. Frisch, J. A. Pople, R. Krishnam, J. S. Binkley, *J. Chem. Phys.* **1984**, 80, 3265–3269.
- [24] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. A. Montgomery Jr, T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez, and J. A. Pople, *Gaussian 03*, Gaussian, Inc. Pittsburgh PA, **2003**.
- [25] a) R. Ditchfield, *Mol. Phys.* **1974**, 27, 789–807; b) F. London, *J. Phys. Radium* **1937**, 8, 397–409.
- [26] S. Miertus, E. Scrocco, J. Tomasi, *Chem. Phys.* **1981**, 55, 117–129.

Received: January 18, 2006

Published Online: March 31, 2006